News

Metabolic and bariatric surgery (MBS) can safely lead to sustained weight loss in Prader-Willi syndrome (PWS) patients, a meta-analysis shows. “It may indeed be time to take a new look at MBS for patients with PWS,” the researchers wrote. The study, “Metabolic and bariatric surgery for obesity…

Children younger than 2 with Prader-Willi syndrome (PWS) show no changes in the levels of free thyroxine (FT4) — the main hormone produced by the thyroid gland — following growth hormone treatment, a Japanese study shows. In older children, those ranging in age from 2 to 7, growth hormone…

The case of a young man with Prader-Willi syndrome who developed Hoffman’s syndrome, a condition marked by muscle weakness due to reduced thyroid gland function, was described in a recent report. The patient’s muscle weakness was effectively treated with thyroid hormone replacement. The study, “Hoffman’s syndrome as the…

Children with Prader-Willi syndrome (PWS) who start on treatment with growth hormone in the first year of life tend to have more normal growth parameters like height and weight, a new study reports. “This longitudinal study showed that younger children with PWS may benefit greatly from [growth hormone] treatment…

Too much insulin — a hormone that controls sugar in blood — may set off weight gain and excessive eating (known as hyperphagia) in children with Prader-Willi syndrome (PWS), a study suggests. High levels of insulin occurred hand in hand with high levels of leptin, a hormone that controls…

EMO-T, a new emotional skill training program, helped children with Prader-Willi syndrome (PWS) express, recognize, understand, and regulate emotions, a study suggested. After EMO-T, scores related to emotional expression and comprehension matched those of control participants without PWS. Regulating and expressing emotions requires prerequisite emotion skills, said the researchers,…

Early treatment with Jintropin, a form of human growth hormone, was associated with improvements in cognition and appeared to slow the decline in motor function among children with Prader-Willi syndrome (PWS), a new study reports. “The present findings of this study add to the growing evidence that [human growth…

Neuren Pharmaceuticals will test its therapeutic candidate NNZ-2591 in children with Prader-Willi syndrome (PWS) in a new Phase 2 clinical trial, the company announced in a press release. The U.S. Food and Drug Administration (FDA) gave Neuren the go-ahead to conduct the trial following the company’s…